Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine;Prevnar 13, la Nueva Vacuna Pneumocóccica Conjugada de 13 Valencias

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages 1516-1524

  Sucher, Allana J ^a   Chahine, Elias B ^b   Nelson, Michael ^a   Sucher, Brandon J ^a  

^a REGIS UNIVERSITY   (United States)

^b PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

Pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGE DISTRIBUTION; APPETITE; ARTICLE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IRRITABILITY; NONHUMAN; PEDIATRICS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP; STREPTOCOCCUS PNEUMONIAE; SWELLING;

ADVISORY COMMITTEES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MULTICENTER STUDIES AS TOPIC; PEDIATRICS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 83155189783     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q347     Document Type: Article

References (35)

1. O'Brien K, Wolfson L, Watt J, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893-902.
2. Bridy-Pappas A, Margolis M, Center K, Isaacman D. Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention. Pharmacotherapy 2005;25:1193-212. DOI 10.1592/phco.2005.25.9.1193
3. Pilishvili T, Lexau C, Farley M, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41. DOI 10.1086/648593
4. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2010;59(RR-11):1-18.
5. Tyrell G. The changing epidemiology of Streptococcus pneumoniae serotype 19A clonal complexes. J Infect Dis 2011;203:1345-7. DOI 10.1093/infdis/jir056
6. Mäkelä PH. Conjugate vaccines-a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 2003;34:249-53.
7. Product information. Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]). Philadelphia: Wyeth Pharmaceuticals Inc, a subsidiary of Pfizer Inc., April 2011.
8. Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007. Morb Mortal Wkly Rep 2010;59:253-57.
9. Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010;126:186-90. DOI 10.1542/peds.2010-1280
10. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Exp Rev Vaccines 2009;8:977-86. DOI 10.1586/erv.09.68
11. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429-36. DOI 10.1542/peds.2008-1702
12. Reinert RR, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010;28:4249-59. DOI 10.1016/j.vaccine.2010.04.020
13. Walker W, Wheeler R, Legg J. Update on the causes, investigation and management of empyema in childhood. Arch Dis Child 2011;96:482-8. DOI 10.1136/adc.2009.165357
14. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent adsorbed) [Prevenar 13]. Drugs 2010;70:1973-86. DOI 0.2165/11205110-000000000-00000
15. Pai VB, Heyneman CA, Erramouspe J. Conjugated heptavalent pneumococcal vaccine. Ann Pharmacother 2002;36:1403-13. DOI 10.1345/aph.1A048
16. Food and Drug Administration. Prevnar 13: clinical review of biologics license application. Rockville, MD: Food and Drug Administration; 2010. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM206341.pdf (accessed 2011 May 18).
17. Jfidar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;3265-72. DOI 10.1016/S0264-410X(03)00230-5
18. Romero-Steiner S, Frasch C, Carlone G, et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006;13:165-9. DOI 10.1128/CVI.13.2.165-169.2006
19. Russell F, Carapetis J, Burton R, et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011;29:535-44. DOI 10.1016/j.vaccine.2010.10.046
20. Yeh S, Gurtman A, Hurley D, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010;126:e493-505. DOI 10.1542/peds.2009-3027
21. Kieninger D, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203. DOI 10.1016/j.vaccine.2010.04.008
22. Bryant K, Block S, Baker S, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics 2010;125:866-75. DOI 10.1542/peds.2009-1405
23. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 2010;17:1017-26. DOI 10.1128/CVI.00062-10
24. Snape M, Klinger C, Daniels E, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 2010;29:e80-90. DOI 10.1097/INF.0b013e3181faa6be
25. Centers for Disease Control and Prevention. General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2011;60(2):1-64.
26. Nahata M, Taketomo C. Pediatrics. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill, 2008:47.
27. Centers for Disease Control and Prevention. Vaccine information statements. http://www.cdc.gov/vaccines/pubs/vis/default.htm (accessed 2011 May 11).
28. Rubin J, McGarry L, Strutton D, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010;28:7634-43. DOI 10.1016/j.vaccine.2010.09.049
29. Chuck A, Jacobs P, Tyrrell G, et al. Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines. Vaccine 2010;28:5485-90. DOI 10.1016/j.vaccine.2010.05.058
30. Product inormation. Synflorix (pneumococcal 10-valent conjugate vaccine). Mississauga, Ontario, Canada: GlaxoSmithKline Inc.; 2009.
31. Rozenbaum M, Sanders E, van Hoek A, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010;340:c2509. DOI 10.1136/bmj.c2509
32. Paradiso P. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children. Clin Infect Dis 2011;52:1241-7. DOI 10.1093/cid/cir142
33. Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 0 through 6 years-United States, 2011. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/0-6yrsschedule-pr.pdf (accessed 2011 Aug 1).
34. Centers for Disease Control and Prevention. Recommended immunization schedule for persons aged 7 through 18 years-United States, 2011. http://www.cdc.gov/vaccines/recs/schedules/downloads/child/7-18yrsschedule-bw.pdf (accessed 2011 Aug 1).
35. Techasaensiri C, Messina AF, Katz K, et al. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr Infect Dis J 2010;29:294-300. DOI 10.1097/INF.0b013e3181c2a229